Q2 2025 Net Revenue of $725 million; GAAP Net Income of $22 million; Diluted Income per Share of $0.07 Adjusted EBITDA of $184 million; Adjusted Diluted EPS of $0.25 Raising 2025 Full Year Guidance Full Debt Refinancing Reduces Interest Cost and Extends Maturities to 2032 BRIDGEWATER, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) --... Read More

Results Reflect Continued Financial Strength and Deleveraging BRIDGEWATER, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced certain unaudited preliminary financial results for the second quarter ended June 30, 2025. The Company plans to report... Read More

BRIDGEWATER, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal”) (Nasdaq: AMRX) announced that its subsidiary, Amneal Pharmaceuticals LLC (the “Issuer”), is seeking to borrow $1.800 billion aggregate principal amount of new seven-year term B loans (the “new term B loans”) under a new term loan... Read More

BRIDGEWATER, N.J., July 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its second quarter 2025 financial results on Tuesday, August 5, 2025, prior to market open. The Company will host an... Read More

Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025 Poised to be among the first wave of biosimilars in the $3.9 billion U.S. omalizumab market and an important growth driver for Amneal BRIDGEWATER, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc . (Nasdaq: AMRX) (“Amneal”... Read More

Key complex product approval in the Affordable Medicines segment this year Commercial launch planned for third quarter of 2025 BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of prednisolone... Read More

BRIDGEWATER, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will participate in two upcoming investor conferences: Jefferies Global Healthcare Conference on June 5, 2025, with company presentation at 9:20 AM ET, and Goldman Sachs Global Healthcare Conference on June 10, 2025, with fireside... Read More

Brekiya ® becomes the first and only DHE autoinjector that allows patients to self-administer the same medication used in hospitals in a ready-to-use form Product will be available for appropriate patients in the second half of 2025 BRIDGEWATER, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX)... Read More

Adds BFS platform technology to provide large-scale production capacity for sterile drug dosage forms, including injectables, ophthalmics and inhalation Expands Amneal’s extensive domestic pharmaceutical manufacturing footprint BRIDGEWATER, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX)... Read More

Q1 2025 Net Revenue of $695 million; GAAP Net Income of $12 million; Diluted Income per Share of $0.04 Adjusted EBITDA of $170 million; Adjusted Diluted EPS of $0.21 Affirming 2025 Full Year Guidance BRIDGEWATER, N.J. / May 02, 2025 / Business Wire / Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today... Read More

BRIDGEWATER, N.J. / Apr 11, 2025 / Business Wire / Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced donations totaling $1.5 million to multiple patient assistance foundations that support individuals living with Parkinson’s disease in honor of... Read More

BRIDGEWATER, N.J. / Apr 08, 2025 / Business Wire / Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its first quarter 2025 financial results on Friday, May 2, 2025, prior to market open. The Company will host an audio... Read More

Analysis of RISE-PD presented at AAN 2025 showed CREXONT treatment significantly improved patients’ Parkinson’s Disease Sleep Scale-2 (PDSS-2) total and sub-scale scores Treatment with CREXONT also resulted in significantly more patients waking up in an “On” state compared to immediate-release CD/LD patients, as part of... Read More

CREXONT added to 3 large national formularies: Veterans Administration, UnitedHealthcare and CVS Health Increases insurance coverage to over 50% of covered lives CREXONT was approved by the U.S. FDA to treat Parkinson’s disease in 2024 BRIDGEWATER, N.J. / Apr 03, 2025 / Business Wire / Amneal Pharmaceuticals, Inc. (Nasdaq:... Read More

First ready-to-use, subcutaneous formulation of Bortezomib now available Marks Amneal’s fourth 505(b)(2) injectable product launch in the last year BRIDGEWATER, N.J. / Apr 01, 2025 / Business Wire / Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and Shilpa Medicare... Read More

BRIDGEWATER, N.J. / Mar 10, 2025 / Business Wire / Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will present at the Barclays 27th Annual Global Healthcare Conference on March, 12, 2025. Chirag Patel, Co-Chief Executive Officer and President, will participate in a fireside chat at 11:00 AM ET. A live webcast of the fireside chat... Read More

Denosumab biosimilar candidates reference Prolia ® and XGEVA ® Amneal looks to expand portfolio to six biosimilars across eight product presentations by 2027 BRIDGEWATER, N.J. / Mar 03, 2025 / Business Wire / Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and... Read More

Full Year 2024 Performance Met or Exceeded All Financial Guidance Metrics Q4 2024 Net Revenue of $731 million; GAAP Net Loss of $31 million; Diluted Loss per Share of $0.10 Q4 2024 Adjusted Net Income (1) of $40 million, Adjusted EBITDA (1) of $155 million; Adjusted Diluted EPS (1) of $0.12 Full Year 2024 Net Revenue of $2.79... Read More

Mesalamine 800 mg delayed-release tablets, referencing ASACOL HD ® Lenalidomide capsules, referencing REVLIMID ® BRIDGEWATER, N.J. / Feb 19, 2025 / Business Wire / Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced the launch of mesalamine 800 mg... Read More

BRIDGEWATER, N.J. / Jan 29, 2025 / Business Wire / Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, prior to market open. The Company... Read More

Approval of three important therapies for dementia, oncology and gastrointestinal disease Granted 180-day exclusivity for memantine/donepezil extended-release capsules Tentative approval of rifaximin, a product for treating IBS-D BRIDGEWATER, N.J. / Jan 23, 2025 / Business Wire / Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX)... Read More

BRIDGEWATER, N.J. / Dec 04, 2024 / Business Wire / Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in two upcoming investor... Read More

Potential first and only DHE autoinjector for tough-to-treat migraines and cluster headaches Exenatide approval highlights Amneal’s capabilities in developing GLP-1 injectables BRIDGEWATER, N.J. / Nov 21, 2024 / Business Wire / Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical... Read More

Q3 2024 Net Revenue of $702 million; GAAP Net Loss of $0.2 million; Diluted Loss per Share of $0.00 Adjusted EBITDA of $158 million; Adjusted Diluted EPS of $0.16 Affirms 2024 Full Year Guidance BRIDGEWATER, N.J. / Nov 08, 2024 / Business Wire / Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today... Read More

Pyridostigmine Bromide Extended Release is a once-daily soman nerve agent pretreatment pyridostigmine product for the U.S. Armed Services and U.S. allies developed utilizing Amneal’s GRANDE ® drug delivery technology Developed with the support of Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear... Read More

BRIDGEWATER, N.J. / Oct 08, 2024 / Business Wire / Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its third quarter 2024 financial results on Friday, November 8, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. The financial results and live webcast will be accessible through the Investor... Read More

Amneal to construct state-of-the-art manufacturing facilities and utilize existing manufacturing network to ensure supply of Metsera’s portfolio of novel injectable and oral development programs, including GLP-1 and amylin receptor agonists Agreement provides Amneal with a new high-growth vector to drive long-term value... Read More

CREXONT now available in U.S. pharmacies nationwide Comprehensive access and affordability services to be made available to Parkinson’s patients and healthcare providers Amneal to hold CREXONT launch symposium and scientific presentations at the International Congress of Parkinson’s Disease and Movement Disorders on Sept. 27 –... Read More

Represents Amneal’s fourth 505(b)(2) injectable approval in 2024 Ready-to-use oncology treatment used for multiple myeloma and mantle cell lymphoma BRIDGEWATER, N.J. / Sep 05, 2024 / Business Wire / Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) and Shilpa Medicare Limited (“Shilpa”) announced U.S.... Read More

Propofol is an essential surgical anesthetic in hospitals that is in chronic shortage Complex emulsion injectable expands Amneal’s injectables portfolio BRIDGEWATER, N.J. / Aug 20, 2024 / Business Wire / Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New... Read More

Q2 2024 Net Revenue of $702 million; GAAP Net Income of $6 million; Diluted Income per Share of $0.02 Adjusted EBITDA of $162 million; Adjusted Diluted EPS of $0.16 Raising 2024 Full Year Guidance CREXONT ® U.S. FDA approval represents an exciting new long-term growth driver BRIDGEWATER, N.J. / Aug 09, 2024 / Business Wire /... Read More

Delivers more “Good On” time with less frequent dosing compared to Immediate Release CD/LD Underscores Amneal’s leadership in Parkinson’s disease and commitment to one million people currently living with Parkinson’s disease in the U.S. CREXONT commercial launch planned in September 2024 BRIDGEWATER, N.J. / Aug 07, 2024 /... Read More

First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter BRIDGEWATER, N.J. / Jul 29, 2024 / Business Wire / Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has received... Read More

BRIDGEWATER, N.J. / Jul 11, 2024 / Business Wire / Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30... Read More

FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 BRIDGEWATER, N.J. / Jul 09, 2024 / Business Wire / Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the... Read More

Builds on successful U.S. biosimilar partnership of 2 oncology products (RELEUKO ® & FYLNETRA ® ) ADL018 is Kashiv’s lead pipeline biosimilar program, currently in Phase III PISCATAWAY, N.J. / Jul 01, 2024 / Business Wire / Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that it has entered into an... Read More

Builds on U.S. biosimilar portfolio of seven products with three commercial and four in pipeline 8 th biosimilar expands portfolio into allergy treatments, a new therapeutic area BRIDGEWATER, N.J. / Jul 01, 2024 / Business Wire / Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the... Read More

Fourth ESG Report Details Company’s Progress Towards Environmental Sustainability and Contributions Toward Building Healthier Communities as a Leading Provider of Accessible Medicines BRIDGEWATER, N.J. / Jun 28, 2024 / Business Wire / Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the... Read More

The Company’s leading R&D capabilities and robust, expanded manufacturing capacity are helping to address chronic market shortages BRIDGEWATER, N.J. / Jun 05, 2024 / Business Wire / Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the continued expansion of its injectables portfolio with... Read More

Significantly expanding access to affordable, life-saving opioid overdose rescue medicine Entered distribution agreement with California; actively engaging with other states and municipalities to expand access BRIDGEWATER, N.J. / May 22, 2024 / Business Wire / Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the... Read More

BRIDGEWATER, N.J. / May 22, 2024 / Business Wire / Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in the 2024 Jefferies Healthcare Conference on June 5, 2024. Chirag will present at 1:30 PM... Read More

Q1 2024 Net Revenue of $659 million; GAAP Net Loss of $92 million; Diluted Loss per Share of $0.30 Adjusted EBITDA of $152 million; Adjusted Diluted EPS of $0.14 Company has reached settlement in principle on a nationwide opioids settlement, payable over ten years Affirming 2024 Full Year Guidance BRIDGEWATER, N.J. / May 03,... Read More

Company launches generic equivalent to OTC NARCAN ® Nasal Spray Provides convenient, affordable access to life-saving medicine BRIDGEWATER, N.J. / Apr 24, 2024 / Business Wire / Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the availability of Over the Counter (“OTC”) Naloxone... Read More

Novel 505(b)(2) presentation of a key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma, does not require reconstitution, dilution, or refrigeration Amneal plans to launch two to three branded oncology 505(b)(2) products per year going forward – this is the first of 2024... Read More

BRIDGEWATER, N.J. / Apr 10, 2024 / Business Wire / Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its first quarter 2024 financial results on Friday, May 3, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m.... Read More

Celebrating Amneal’s recent listing on the Nasdaq Stock Exchange BRIDGEWATER, N.J. / Mar 28, 2024 / Business Wire / Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, today announced that Chirag and Chintu Patel, Co-founders and Co-Chief Executive Officers, will ring the... Read More

Product references branded Ciprodex Represents another complex, high value new product BRIDGEWATER, N.J. / Mar 25, 2024 / Business Wire / Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application (“ANDA”) approval from the U.S. Food and Drug... Read More

Full Year 2023 Performance Met or Exceeded Financial Guidance Metrics Q4 2023 Net Revenue of $617 million; GAAP Net Loss of $99 million; Diluted Loss per Share of $0.40 Q4 2023 Adjusted Net Income (1) of $44 million, Adjusted EBITDA (1) of $142 million; Adjusted Diluted EPS (1) of $0.14 Full Year 2023 Net Revenue of $2.39... Read More

BRIDGEWATER, N.J. & CADEMPINO, Switzerland / Feb 27, 2024 / Business Wire / Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced that it has entered into an exclusive licensing agreement with Zambon Biotech SA, part of the Zambon group (“Zambon”), for IPX203 in the European Union, United... Read More

BRIDGEWATER, N.J. / Feb 13, 2024 / Business Wire / Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer, will participate in the following investor conference. Barclays 26th Annual Global Healthcare Conference March 13, 2024 Miami, FL Fireside chat – 8:30 AM ET One-on-one... Read More

BRIDGEWATER, N.J. / Jan 31, 2024 / Business Wire / Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its fourth quarter and full year 2023 financial results on Friday, March 1, 2024, prior to market open. The Company will host a conference call and live webcast with the investment... Read More

Fluorometholone Ophthalmic Suspension, USP, 0.1% Product has 180-day competitive generic therapy exclusivity BRIDGEWATER, N.J. / Jan 10, 2024 / Business Wire / Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced the approval and launch of fluorometholone ophthalmic suspension. The product... Read More

More new product innovations in 2023, as compared to 26 in 2022 13 new products launched in the fourth quarter of 2023 BRIDGEWATER, N.J. / Jan 04, 2024 / Business Wire / Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) today announces that it has launched 39 new retail and injectable medicines in 2023, as compared to 26... Read More

Nasdaq move will be effective on December 27, 2023 BRIDGEWATER, N.J. / Dec 15, 2023 / Business Wire / Amneal Pharmaceuticals, Inc . (“Amneal”) (NYSE: AMRX) today announced that it will transfer its stock exchange listing to the Nasdaq Stock Market (“Nasdaq”) from the New York Stock Exchange (“NYSE”). The Company expects the Nasdaq listing to occur on December 27, 2023 and will continue to trade under the current symbol... Read More

ONGENTYS ® (opicapone) is a leading adjunctive therapy for the treatment of Parkinson’s Disease Complements Amneal’s existing Parkinson’s franchise and further expands specialty portfolio BRIDGEWATER, N.J. & PORTO, Portugal / Dec 07, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and BIAL - Portela... Read More

Partnering with Strides to commercialize recently U.S. FDA approved product Represents another new product launch for Amneal in 2023 BRIDGEWATER, N.J. / Dec 01, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) and Strides Pharma Science Limited (“Strides”) today announced the... Read More

Q3 2023 Net Revenue of $620 million; GAAP Net Income of $10 million; Diluted EPS of $0.06 Q3 2023 Adjusted Net Income (1) of $60 million; Adjusted EBITDA (1) of $154 million; Adjusted Diluted EPS (1) of $0.19 Affirmed Previously Announced Increased 2023 Full Year Guidance BRIDGEWATER, N.J. / Nov 07, 2023 / Business Wire /... Read More

BRIDGEWATER, N.J. / Nov 03, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in the below investor conferences. Jefferies 14 th Annual Global Healthcare Conference November... Read More

Biosimilar candidates referencing Prolia ® and XGEVA ® Builds on first year success of Amneal’s initial three biosimilar launches Expands existing biosimilar partnership with mAbxience BRIDGEWATER, N.J. / Oct 12, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the... Read More

BRIDGEWATER, N.J. / Oct 05, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2023 financial results on Tuesday, November 7, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30... Read More

Key injectable currently on the U.S. FDA shortage list Received Competitive Generic Therapy approval designation BRIDGEWATER, N.J. / Sep 06, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application (“ANDA”) approval from the... Read More

1 st product approval in China represents Amneal’s entry in second largest pharmaceutical market Expects international expansion will be another key vector for long-term growth and impact BRIDGEWATER, N.J. / Sep 06, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it... Read More

Key ADHD medicine on the U.S. FDA shortage product list Represents another high-value product approval for Amnea l BRIDGEWATER, N.J. / Sep 06, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application (ANDA) approval from the... Read More

Senior members of the U.S. Government Visit One of Amneal’s 12 Manufacturing Sites BRIDGEWATER, N.J. / Aug 29, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that a delegation of senior members of the U.S. Department of Health and Human Services (HHS) and U.S. Food... Read More

BRIDGEWATER, N.J. / Aug 25, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 2023 Wells Fargo Healthcare Conference on September 7, 2023 in Boston.... Read More

IPX203 demonstrated statistically significant improvement in daily “Good On” time compared to optimized IR CD/LD, with fewer daily doses BRIDGEWATER, N.J. / Aug 24, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that JAMA Neurology has published results from the RISE-PD clinical study... Read More

Q2 2023 Net Revenue of $599 million; GAAP Net Income of $12 million; Diluted EPS of $0.08 Q2 2023 Adjusted Net Income (1) of $57 million; Adjusted EBITDA (1) of $146 million; Adjusted Diluted EPS (1) of $0.19 Raising 2023 Full Year Guidance BRIDGEWATER, N.J. / Aug 04, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE:... Read More

Represents three high-value medicines across complex dosage forms BRIDGEWATER, N.J. / Jul 26, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has submitted Abbreviated New Drug Applications (“ANDA”) to the U.S. Food and Drug Administration (FDA) for three key... Read More

BRIDGEWATER, N.J. / Jul 06, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2023 financial results on Friday August 4, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m.... Read More

Letter requests additional pharmacokinetic data No clinical efficacy or manufacturing issues identified BRIDGEWATER, N.J. / Jul 03, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug... Read More

Launches authorized generic for Xyrem ® (sodium oxybate) in the U.S., representing another new complex generic product launch Receives U.S. FDA approval for five new complex generics in the second quarter Remains on track to deliver more than 30 new generic launches in 2023 BRIDGEWATER, N.J. / Jul 03, 2023 / Business Wire /... Read More

Newly Released Report Details Company’s Progress and Contributions Toward Good Health and Well-Being as a Leading Provider of Affordable Medicines BRIDGEWATER, N.J. / Jun 15, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the release of its third annual (2022)... Read More

Adds first ready-to-use presentation of key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma Represents a high value, complex product launch for Amneal’s expanding injectable portfolio BRIDGEWATER, N.J. / Jun 14, 2023 / Business Wire / Amneal Pharmaceuticals , Inc. (NYSE: AMRX)... Read More

BRIDGEWATER, N.J. / May 24, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 2023 Jefferies Healthcare Conference held on June 7, 2023 in New York... Read More

Third of three approved U.S. oncology biosimilars Amneal has launched BRIDGEWATER, N.J. / May 16, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of FYLNETRA™ (pegfilgrastim-pbbk), a biosimilar referencing Neulasta ® in a pre-filled single-dose... Read More

Q1 2023 Net Revenue of $558 million; GAAP Net Loss of $7 million; Diluted Loss per Share of $0.05 Adjusted EBITDA (1) of $116 million; Adjusted Diluted EPS (1) of $0.12 Affirming 2023 Full Year Guidance BRIDGEWATER, N.J. / May 05, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”)... Read More

BRIDGEWATER, N.J. / Apr 17, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 22nd Annual Needham Virtual Healthcare Conference held on April 19,... Read More

BRIDGEWATER, N.J. / Apr 17, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced certain unaudited preliminary financial results for the first quarter ended March 31, 2023. The Company is also affirming financial guidance for the year ending December 31, 2023, which was... Read More

BRIDGEWATER, N.J. / Apr 12, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2023 financial results on Friday May 5, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m.... Read More

BRIDGEWATER, N.J. / Mar 02, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New Drug Application (ANDA) for naloxone hydrochloride nasal spray, USP, 4mg, which is the generic version of Narcan ® and is used in... Read More

BRIDGEWATER, N.J. / Mar 02, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its results today for the fourth quarter and full year ended December 31, 2022. “2022 was a year of solid execution and very good progress in advancing key strategic priorities marked by a robust... Read More

BRIDGEWATER, N.J. / Jan 31, 2023 / Business Wire / Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2022 financial results on Thursday March 2, 2023, prior to market open. The Company will host a conference call and live webcast with the investment... Read More

Long-term collaboration to bring Amneal generic products to market in Europe, Australia, and New Zealand Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has signed a long-term license agreement with Orion Corporation (OMXH: ORNBV & ORNAV) to commercialize a number of Amneal’s complex... Read More

8 new product launches in Q4 closes out another successful year of innovation First approval of a large volume bag product signals further expansion of injectables business BRIDGEWATER, N.J.--( BUSINESS WIRE )-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the Company has... Read More